More about
Advanced Gastroesophageal Adenocarcinoma
News
January 27, 2025
1 min read
Save
Combination does not extend survival vs. chemotherapy in gastroesophageal cancer
The addition of lenvatinib and pembrolizumab to chemotherapy did not extend OS for certain patients with advanced gastroesophageal adenocarcinoma, according to the agents’ manufacturers.